09/ 939,883

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	AUG 22	Indexing from 1927 to 1936 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY
NEWS 28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS 29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS 32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS 33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS 34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS 35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS 36	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS 37	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation
NEWS 38	AUG 18	Simultaneous left and right truncation added to ANABSTR

09/ 939,883

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:47:04 ON 28 AUG 2003

=> file reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:47:13 ON 28 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 AUG 2003  HIGHEST RN 573925-63-0
DICTIONARY FILE UPDATES:  26 AUG 2003  HIGHEST RN 573925-63-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09939883.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```







G1 [@1], [@2]

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 ful
FULL SEARCH INITIATED 14:47:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  11043 TO ITERATE

100.0% PROCESSED   11043 ITERATIONS                          128 ANSWERS
SEARCH TIME: 00.00.01

L2          128 SEA SSS FUL L1

=> file caold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             148.15     148.36

FILE 'CAOLD' ENTERED AT 14:47:47 ON 28 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.
```

09/ 939,883

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l2
L3 0 L2

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.40	148.76

FILE 'CAPLUS' ENTERED AT 14:47:55 ON 28 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 Aug 2003 VOL 139 ISS 9
FILE LAST UPDATED: 27 Aug 2003 (20030827/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L4 2 L2

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:185085 CAPLUS
DOCUMENT NUMBER: 136:247596
TITLE: Preparation of 7-aryl-4-(1-azacycloalkyl)quin(az)olines and analogs as NPY receptor antagonists
INVENTOR(S): Breu, Volker; Dautzenberg, Frank; Guerry, Philippe; Nettekoven, Matthias Heinrich; Pflieger, Philippe
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020488	A2	20020314	WO 2001-EP10014	20010830
WO 2002020488	A3	20020516		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002052356	A1	20020502	US 2001-939883	20010827
AU 2002010474	A5	20020322	AU 2002-10474	20010830
BR 2001013710	A	20030603	BR 2001-13710	20010830
EP 1318981	A2	20030618	EP 2001-978324	20010830

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: EP 2000-119262 A 20000906
WO 2001-EP10014 W 20010830

OTHER SOURCE(S): MARPAT 136:247596

GI



I

Prepared Version

AB Title compds. [I; R1 = (cyclo)alkyl, CF3, aralkyl; R2 = H, halo, alkyl, alkoxy, etc.; R3 = (hetero)aryl; NR4R5 = (un)substituted heterocyclyl; Z1 = CH or N] were prepd. Thus, 4-chloro-7-iodo-2-methylquinoline was aminated by pyrrolidine and the product arylated by 3-ClC6H4B(OH)2 to give I [R1 = Me, R2 = H, R3 = 7-(3-chlorophenyl), R4R5 = (CH2)4, Z1 = CH]. Data for biol. activity of I were given.

IT **403849-18-3P 403849-19-4P 403849-20-7P**
403849-21-8P 403849-22-9P 403849-23-0P
403849-24-1P 403849-25-2P 403849-26-3P
403849-27-4P 403849-28-5P 403849-29-6P
403849-30-9P 403849-31-0P 403849-32-1P
403849-33-2P 403849-34-3P 403849-35-4P
403849-43-4P 403849-44-5P 403849-45-6P
403849-46-7P 403849-48-9P 403849-49-0P
403849-90-1P 403849-92-3P 403849-96-7P
403849-98-9P 403850-00-0P 403850-02-2P
403850-04-4P 403850-06-6P 403850-08-8P
403850-10-2P 403850-12-4P 403850-14-6P
403850-16-8P 403850-17-9P 403850-18-0P
403850-19-1P 403850-20-4P 403850-22-6P
403850-23-7P 403850-25-9P 403850-27-1P
403850-29-3P 403850-31-7P 403850-32-8P
403850-33-9P 403850-35-1P 403850-37-3P
403850-39-5P 403850-40-8P 403850-41-9P
403850-43-1P 403850-45-3P 403850-47-5P
403850-50-0P 403850-52-2P 403850-54-4P
403850-56-6P 403850-58-8P 403850-60-2P
403850-62-4P 403850-64-6P 403850-65-7P
403853-09-8P 403853-11-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 7-aryl-4-(1-azacycloalkyl)quin(az)olines and analogs as NPY receptor antagonists)

RN 403849-18-3 CAPLUS
CN Quinoline, 7-(3-chlorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-19-4 CAPLUS
CN Quinoline, 2-methyl-4-(1-pyrrolidinyl)-7-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 403849-20-7 CAPLUS
CN Benzenamine, 3-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]- (9CI) (CA INDEX NAME)



RN 403849-21-8 CAPLUS
CN Ethanone, 1-[4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 403849-22-9 CAPLUS

CN Quinoline, 2-methyl-7-phenyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-23-0 CAPLUS
CN Quinoline, 7-(4-methoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-24-1 CAPLUS
CN Quinoline, 2-methyl-4-(1-pyrrolidinyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 403849-25-2 CAPLUS
CN Quinoline, 2-methyl-7-(3-pyridinyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-26-3 CAPLUS
CN Quinoline, 2-methyl-7-(5-pyrimidinyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX

NAME)



RN 403849-27-4 CAPLUS
CN Quinoline, 2-methyl-4-(1-piperidinyl)-7-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 403849-28-5 CAPLUS
CN Quinoline, 7-(3-chlorophenyl)-2-methyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 403849-29-6 CAPLUS
CN Ethanone, 1-[4-[2-methyl-4-(1-piperidinyl)-7-quinolinyl]phenyl]- (9CI) (CA INDEX NAME)



RN 403849-30-9 CAPLUS
CN Benzenamine, 3-[2-methyl-4-(1-piperidinyl)-7-quinolinyl]- (9CI) (CA INDEX NAME)



RN 403849-31-0 CAPLUS
CN Quinoline, 7-(4-methoxyphenyl)-2-methyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 403849-32-1 CAPLUS
CN Quinoline, 2-methyl-4-(1-piperidinyl)-7-(2-thienyl)- (9CI) (CA INDEX NAME)



09/ 939,883

RN 403849-33-2 CAPLUS
CN Quinoline, 2-methyl-7-phenyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 403849-34-3 CAPLUS
CN Quinoline, 7-(1H-indol-5-yl)-2-methyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 403849-35-4 CAPLUS
CN Quinoline, 2-methyl-4-(1-piperidinyl)-7-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 403849-43-4 CAPLUS
CN Quinoline, 4-(3,4-dihydro-2(1H)-isoquinolinyl)-2-methyl-7-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 403849-44-5 CAPLUS
CN Quinoline, 5-(3-chlorophenyl)-2-methyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 403849-45-6 CAPLUS
CN Quinoline, 2-methyl-4-(1-piperidinyl)-5-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 403849-46-7 CAPLUS
CN Quinoline, 5-(3-chlorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-48-9 CAPLUS
CN Quinoline, 4-(hexahydro-1H-azepin-1-yl)-2-methyl-7-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 403849-49-0 CAPLUS
CN Quinoline, 6-(3-chlorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403849-90-1 CAPLUS
CN Formic acid, compd. with 7-(4-ethylphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403849-89-8
CMF C22 H24 N2



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403849-92-3 CAPLUS
CN Formic acid, compd. with 7-(3,4-dimethoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

09/ 939,883

CM 1

CRN 403849-91-2
CMF C22 H24 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403849-96-7 CAPLUS
CN Formic acid, compd. with 7-(2,6-difluorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403849-95-6
CMF C20 H18 F2 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403849-98-9 CAPLUS
CN Formic acid, compd. with 7-(2,4-dimethoxyphenyl)-2-methyl-4-(1-

pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403849-97-8
CMF C22 H24 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-00-0 CAPLUS
CN Formic acid, compd. with 2-methyl-4-(1-pyrrolidinyl)-7-[4-(trifluoromethyl)phenyl]quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403849-99-0
CMF C21 H19 F3 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-02-2 CAPLUS

09/ 939,883

CN Formic acid, compd. with 2-methyl-7-[4-(methylthio)phenyl]-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-01-1
CMF C21 H22 N2 S



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-04-4 CAPLUS
CN Formic acid, compd. with 7-(2-methoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-03-3
CMF C21 H22 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



09/ 939,883

RN 403850-06-6 CAPLUS
CN Formic acid, compd. with 7-(3-ethoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-05-5
CMF C22 H24 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-08-8 CAPLUS
CN Formic acid, compd. with N-[3-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-07-7
CMF C22 H23 N3 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-10-2 CAPLUS
CN Formic acid, compd. with 2-methyl-4-(1-pyrrolidinyl)-7-[4-(trifluoromethoxy)phenyl]quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-09-9
CMF C21 H19 F3 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-12-4 CAPLUS
CN Formic acid, compd. with 7-(1,3-benzodioxol-5-yl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-11-3
CMF C21 H20 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-14-6 CAPLUS
CN Formic acid, compd. with 7-(2-benzofuranyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-13-5
CMF C22 H20 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-16-8 CAPLUS
CN Formic acid, compd. with 7-benzo[b]thien-2-yl-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-15-7
CMF C22 H20 N2 S



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-17-9 CAPLUS
CN Quinoline, 7-(3-chloro-4-fluorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403850-18-0 CAPLUS
CN Formic acid, compd. with 7-(3-chloro-4-fluorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-17-9
CMF C20 H18 Cl F N2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-19-1 CAPLUS
CN Ethanone, 1-[5-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]-2-thienyl]-(9CI) (CA INDEX NAME)



RN 403850-20-4 CAPLUS

09/ 939,883

CN Formic acid, compd. with 1-[5-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]-2-thienyl]ethanone (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-19-1
CMF C20 H20 N2 O S



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-22-6 CAPLUS
CN Quinoline, 7-(3,4-dichlorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403850-23-7 CAPLUS
CN Formic acid, compd. with 7-(3,4-dichlorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-22-6
CMF C20 H18 Cl2 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-25-9 CAPLUS
CN Formic acid, compd. with 7-(2-fluorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-24-8
CMF C20 H19 F N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-27-1 CAPLUS
CN Formic acid, compd. with 2-methyl-7-(1-naphthalenyl)-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-26-0

09/ 939,883

CMF C24 H22 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-29-3 CAPLUS
CN Formic acid, compd. with 7-(2-chlorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-28-2
CMF C20 H19 Cl N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-31-7 CAPLUS
CN Formic acid, compd. with 7-(4-ethenylphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-30-6
CMF C22 H22 N2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-32-8 CAPLUS
CN Quinoline, 7-(3,5-dichlorophenyl)-2-methyl-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403850-33-9 CAPLUS
CN Formic acid, compd. with 7-(3,5-dichlorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-32-8
CMF C20 H18 Cl2 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-35-1 CAPLUS
CN Formic acid, compd. with 7-(3-methoxyphenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-34-0
CMF C21 H22 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-37-3 CAPLUS
CN Benzoic acid, 3-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]-, ethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 403850-36-2
CMF C23 H24 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-39-5 CAPLUS
CN Benzoic acid, 4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]-, ethyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 403850-38-4
CMF C23 H24 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-40-8 CAPLUS
CN Phenol, 2-methoxy-4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]- (9CI) (CA INDEX NAME)



RN 403850-41-9 CAPLUS
CN Formic acid, compd. with 2-methoxy-4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-40-8
CMF C21 H22 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

RN 403850-43-1 CAPLUS
CN Formic acid, compd. with N-[4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenyl]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-42-0
CMF C22 H23 N3 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-45-3 CAPLUS
CN Formic acid, compd. with N,N-dimethyl-4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]benzenamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-44-2
CMF C22 H25 N3



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-47-5 CAPLUS
CN Formic acid, compd. with N-methyl-4-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-46-4
CMF C22 H23 N3 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-50-0 CAPLUS
CN Formic acid, compd. with 3-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-49-7
CMF C20 H20 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-52-2 CAPLUS
CN Formic acid, compd. with 2-methoxy-5-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-51-1

09/ 939,883

CMF C21 H22 N2 O2



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH—OH

RN 403850-54-4 CAPLUS
CN Formic acid, compd. with 7-(2,6-dimethoxy-3-pyridinyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-53-3
CMF C21 H23 N3 O2



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH—OH

RN 403850-56-6 CAPLUS
CN Formic acid, compd. with 2-[2-methyl-4-(1-pyrrolidinyl)-7-quinolinyl]phenol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-55-5
CMF C20 H20 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-58-8 CAPLUS
CN Formic acid, compd. with 2-methyl-7-(4-phenoxyphenyl)-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-57-7
CMF C26 H24 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-60-2 CAPLUS
CN Formic acid, compd. with 7-(2,6-dichlorophenyl)-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

09/ 939,883

CM 1

CRN 403850-59-9
CMF C20 H18 Cl2 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-62-4 CAPLUS
CN Formic acid, compd. with 2-methyl-4-(1-pyrrolidinyl)-7-[3-(trifluoromethoxy)phenyl]quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-61-3
CMF C21 H19 F3 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403850-64-6 CAPLUS
CN Formic acid, compd. with 2-methyl-4-(1-pyrrolidinyl)-7-[2-(trifluoromethoxy)phenyl]quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-63-5
CMF C21 H19 F3 N2 O



CM 2

CRN 64-18-6
CMF C H2 O2



RN 403850-65-7 CAPLUS
CN Quinoline, 2-methyl-7-(2-naphthalenyl)-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



RN 403853-09-8 CAPLUS
CN Formic acid, compd. with 2-methyl-7-(2-naphthalenyl)-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403850-65-7
CMF C24 H22 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 403853-11-2 CAPLUS
CN Formic acid, compd. with 7-[3,5-bis(trifluoromethyl)phenyl]-2-methyl-4-(1-pyrrolidinyl)quinoline (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 403853-10-1
CMF C22 H18 F6 N2



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:31438 CAPLUS
DOCUMENT NUMBER: 136:102370
TITLE: Preparation of tetrahydropyridine or piperidine heterocyclic derivatives and their affinity for CRF receptors
INVENTOR(S): Nakazato, Atsuro; Kumagai, Toshihito; Okubo, Taketoshi; Kameo, Kazuya
PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002002549 A1 20020110 WO 2001-JP5806 20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1299378 A1 20030409 EP 2001-947819 20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
NO 2002006125 A 20030204 NO 2002-6125 20021219
PRIORITY APPLN. INFO.: JP 2000-204021 A 20000705
JP 2000-270535 A 20000906
WO 2001-JP5806 W 20010704
OTHER SOURCE(S): MARPAT 136:102370

AB Tetrahydropyridine or piperidine heterocyclic derivs. with high affinity for CRF receptors were prepd. E.g., 5-(4-carbamoyl-1,2,3,6-tetrahydropyridin-1-yl)-2-(N-ethyl-2,4-dichloroanilino)-4-methylthiazole was prepd. by bromination of 2-(N-ethyl-2,4-dichloroanilino)-4-methylthiazole hydrochloride, followed by reaction with 5-carbamoyl-1,2,3,6-tetrahydropyridine hydrochloride.

IT **388122-48-3P 388122-49-4P 388122-50-7P**
388122-52-9P 388122-53-0P 388122-54-1P
388122-55-2P 388122-56-3P 388122-57-4P
388122-58-5P 388122-59-6P 388122-60-9P
388122-61-0P 388122-62-1P 388122-63-2P
388122-64-3P 388122-65-4P 388122-67-6P
388122-68-7P 388122-69-8P 388122-70-1P
388122-71-2P 388122-72-3P 388122-73-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tetrahydropyridine or piperidine heterocyclic derivs. and their affinity for CRF receptors)

RN 388122-48-3 CAPLUS

CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-49-4 CAPLUS
CN 4-Pyridinecarboxamide, 1,2,3,6-tetrahydro-1-[2-methyl-8-(2,4,6-trimethylphenyl)-4-quinolinyl]- (9CI) (CA INDEX NAME)



RN 388122-50-7 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dimethoxyphenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-52-9 CAPLUS
CN 4-Pyridineacetamide, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-53-0 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-[2-chloro-4-(trifluoromethyl)phenyl]-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-54-1 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-[2-chloro-4-(trifluoromethoxy)phenyl]-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-55-2 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,6-dimethoxy-3-pyridinyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-56-3 CAPLUS
CN 4-Pyridinecarboxamide, 1-[6-chloro-8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-57-4 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-2,6-dimethyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-58-5 CAPLUS
CN 4-Pyridinecarboxylic acid, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-59-6 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-6-fluoro-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-60-9 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-2-methyl-6-(trifluoromethoxy)-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-61-0 CAPLUS
CN 4-Pyridinecarboxylic acid, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 388122-62-1 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-63-2 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-[2,6-dimethyl-4-(trifluoromethyl)phenyl]-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-64-3 CAPLUS
CN 3-Pyridinecarboxamide, 1,2,5,6-tetrahydro-1-[2-methyl-8-[4-(trifluoromethyl)phenyl]-4-quinolinyl]- (9CI) (CA INDEX NAME)



RN 388122-65-4 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dimethoxyphenyl)-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-67-6 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-6-fluoro-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-68-7 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-2-methyl-6-(trifluoromethoxy)-4-quinolinyl]-1,2,5,6-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 388122-69-8 CAPLUS
CN Acetamide, 2-[1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-4-piperidinylidene]- (9CI) (CA INDEX NAME)



RN 388122-70-1 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-6-(dimethylamino)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-71-2 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-6-(dimethylamino)-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 388122-72-3 CAPLUS
CN 4-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-5-fluoro-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388122-73-4 CAPLUS
CN 3-Pyridinecarboxamide, 1-[8-(2,4-dichlorophenyl)-5-fluoro-2-methyl-4-quinolinyl]-1,2,5,6-tetrahydro- (9CI) (CA INDEX NAME)



IT **388123-52-2P 388123-59-9P 388123-60-2P**
388123-61-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of tetrahydropyridine or piperidine heterocyclic derivs. and their affinity for CRF receptors)

RN 388123-52-2 CAPLUS
CN 4-Pyridinecarbonitrile, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



RN 388123-59-9 CAPLUS
CN Acetic acid, [1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-4-piperidinylidene]-, ethyl ester (9CI) (CA INDEX NAME)



RN 388123-60-2 CAPLUS
CN Acetic acid, [1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-4-piperidinylidene]- (9CI) (CA INDEX NAME)



RN 388123-61-3 CAPLUS
CN 4-Pyridineacetic acid, 1-[8-(2,4-dichlorophenyl)-2-methyl-4-quinolinyl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:47:04 ON 28 AUG 2003)

FILE 'REGISTRY' ENTERED AT 14:47:13 ON 28 AUG 2003
L1 STRUCTURE UPLOADED
L2 128 S L1 FUL

FILE 'CAOLD' ENTERED AT 14:47:47 ON 28 AUG 2003
L3 0 S L2

FILE 'CAPLUS' ENTERED AT 14:47:55 ON 28 AUG 2003
L4 2 S L2

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.91	158.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

STN INTERNATIONAL LOGOFF AT 14:48:56 ON 28 AUG 2003